Trial Profile
Prospective observational study to predict sensitive marker after administration of nintedanib in patients with idiopathic pulmonary fibrosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2016
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Pulmonary fibrosis
- Focus Biomarker; Pharmacodynamics
- 28 May 2016 New trial record